BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
T.W. Barber, M.S. Hofman, B.N.J. Thomson, R.J. Hicks. The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectableEuropean Journal of Surgical Oncology (EJSO) 2012; 38(1): 64 doi: 10.1016/j.ejso.2011.08.129
2
Günter Klöppel, Paul Komminoth, Ph. U. Heitz. Pathologie2016; : 815 doi: 10.1007/978-3-642-04566-0_24
3
Beata Jabłońska, Daria Dranka-Bojarowska, Hanna Palacz, Adam Lewiński, Paweł Lampe. Surgical Treatment of Pancreatic Neuroendocrine Tumours - Clinical ExperiencePolish Journal of Surgery 2011; 83(4) doi: 10.2478/v10035-011-0033-5
4
Anna Sowa-Staszczak, Robert Chrzan, Dorota Pach, Agnieszka Stefańska, Monika Tomaszuk, Monika Buziak-Bereza, Maciej Kołodziej, Elwira Przybylik-Mazurek, Alicja Hubalewska-Dydejczyk. Are RECIST criteria sufficient to assess response to therapy in neuroendocrine tumors?Clinical Imaging 2012; 36(4): 360 doi: 10.1016/j.clinimag.2011.11.005
5
Dik J. Kwekkeboom, Eric P. Krenning. Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine TumorsHematology/Oncology Clinics of North America 2016; 30(1): 179 doi: 10.1016/j.hoc.2015.09.009
6
Giuseppe Lo Russo, Sara Pusceddu, Natalie Prinzi, Martina Imbimbo, Claudia Proto, Diego Signorelli, Milena Vitali, Monica Ganzinelli, Marco Maccauro, Roberto Buzzoni, Ettore Seregni, Filippo de Braud, Marina Chiara Garassino. Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumorsTumor Biology 2016; 37(10): 12991 doi: 10.1007/s13277-016-5258-9
7
Marianne Pavel, Eric Baudin, Anne Couvelard, Eric Krenning, Kjell Öberg, Thomas Steinmüller, Martin Anlauf, Bertram Wiedenmann, Ramon Salazar. ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown PrimaryNeuroendocrinology 2012; 95(2): 157 doi: 10.1159/000335597
8
Tak Geun Oh, Moon Jae Chung, Jeong Yeop Park, Seung Min Bang, Seung Woo Park, Jae Bok Chung, Si Young Song. Prognostic Factors and Characteristics of Pancreatic Neuroendocrine Tumors: Single Center ExperienceYonsei Medical Journal 2012; 53(5): 944 doi: 10.3349/ymj.2012.53.5.944
9
Tessa Brabander, Jaap J.M. Teunissen, Casper H.J. Van Eijck, Gaston J.H. Franssen, Richard A. Feelders, Wouter W. de Herder, Dik J. Kwekkeboom. Peptide receptor radionuclide therapy of neuroendocrine tumoursBest Practice & Research Clinical Endocrinology & Metabolism 2016; 30(1): 103 doi: 10.1016/j.beem.2015.10.005
10
Daniel Kaemmerer, Ralph M. Wirtz, Elke K. Fischer, Merten Hommann, Jörg Sänger, Vikas Prasad, Elisa Specht, Richard P. Baum, Stefan Schulz, Amelie Lupp. Analysis of Somatostatin Receptor 2A Immunohistochemistry, RT-qPCR, and In Vivo PET/CT Data in Patients with Pancreatic Neuroendocrine NeoplasmPancreas 2015; : 1 doi: 10.1097/MPA.0000000000000316
11
Jordan M. Cloyd, Kiyohiko Omichi, Takashi Mizuno, Yoshikuni Kawaguchi, Ching-Wei D. Tzeng, Claudius Conrad, Yun Shin Chun, Thomas A. Aloia, Matthew H. G. Katz, Jeffrey E. Lee, Daniel Halperin, James Yao, Jean-Nicolas Vauthey, Arvind Dasari. Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver MetastasesAnnals of Surgical Oncology 2018; 25(6): 1709 doi: 10.1245/s10434-018-6468-8
12
S. Gül-Klein, R. Schmuck, D. P. Modest, J. Pratschke. Therapie kolorektaler und nichtkolorektaler Lebermetastasen: Sinnhaftigkeit neoadjuvanter TherapiekonzepteDer Chirurg 2020; 91(5): 396 doi: 10.1007/s00104-020-01133-7
13
Richard P. Baum, Harshad R. Kulkarni, Cecilia Carreras. Peptides and Receptors in Image-Guided Therapy: Theranostics for Neuroendocrine NeoplasmsSeminars in Nuclear Medicine 2012; 42(3): 190 doi: 10.1053/j.semnuclmed.2012.01.002
14
M Shah, R Da Silva, C Gravekamp, S K Libutti, T Abraham, E Dadachova. Targeted radionuclide therapies for pancreatic cancerCancer Gene Therapy 2015; 22(8): 375 doi: 10.1038/cgt.2015.32
15
Michael Gabriel. Radiopeptidtherapie – der „Mustang“ in der Therapie von neuroendokrinen Tumoren des gastroentero-pankreatischen Systems?Journal für Klinische Endokrinologie und Stoffwechsel 2018; 11(3): 81 doi: 10.1007/s41969-018-0034-7
16
Nader Hirmas, Raya Jadaan, Akram Al-Ibraheem. Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future PerspectivesNuclear Medicine and Molecular Imaging 2018; 52(3): 190 doi: 10.1007/s13139-018-0517-x
17
Anna Sowa-Staszczak, Alicja Hubalewska-Dydejczyk, Monika Tomaszuk. Theranostics, Gallium-68, and Other RadionuclidesRecent Results in Cancer Research 2013; 194: 479 doi: 10.1007/978-3-642-27994-2_27
18
Iraklis Perysinakis, Chrysanthi Aggeli, Gregory Kaltsas, George N. Zografos. Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality?Hormones 2016; 15(1): 15 doi: 10.1007/BF03401399
19
Costanza Chiapponi, Nadine Lürssen, Birgit Cremer, Roger Wahba, Uta Drebber, Michael Faust, Matthias Schmidt, Dirk L. Stippel. Peptide receptor radionuclide therapy as a two-step strategy for initially unresectable liver disease from neuroendocrine tumors: a single-center experienceEndocrine 2020;  doi: 10.1007/s12020-020-02341-1
20
Mauro Cives, Jonathan Strosberg. Radionuclide Therapy for Neuroendocrine TumorsCurrent Oncology Reports 2017; 19(2) doi: 10.1007/s11912-017-0567-8
21
Hendrik Bergsma, Esther I. van Vliet, Jaap J.M. Teunissen, Boen L.R. Kam, Wouter W. de Herder, Robin P. Peeters, Eric P. Krenning, Dik J. Kwekkeboom. Peptide receptor radionuclide therapy (PRRT) for GEP-NETsBest Practice & Research Clinical Gastroenterology 2012; 26(6): 867 doi: 10.1016/j.bpg.2013.01.004
22
Marco Schiavo Lena, Stefano Partelli, Paola Castelli, Valentina Andreasi, Chanel Elisha Smart, Eleonora Pisa, Mirco Bartolomei, Emilio Bertani, Giuseppe Zamboni, Massimo Falconi, Claudio Doglioni. Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT)Endocrine Pathology 2020; 31(2): 119 doi: 10.1007/s12022-020-09623-4
23
Mila Todorović-Tirnanić, Daniel Kaemmerer, Vikas Prasad, Merten Hommann, Richard P. Baum. Theranostics, Gallium-68, and Other RadionuclidesRecent Results in Cancer Research 2013; 194: 487 doi: 10.1007/978-3-642-27994-2_28
24
Richard P. Baum, Harshad R. Kulkarni. Therapeutic Nuclear MedicineMedical Radiology 2014; : 583 doi: 10.1007/174_2013_945
25
Sze Ting Lee, Harshad R. Kulkarni, Aviral Singh, Richard P. Baum. Theranostics of Neuroendocrine TumorsVisceral Medicine 2017; 33(5): 358 doi: 10.1159/000480383
26
Wouter A van der Zwan, Lisa Bodei, Jan Mueller-Brand, Wouter W de Herder, Larry K Kvols, Dik J Kwekkeboom. GEP–NETs UPDATE: Radionuclide therapy in neuroendocrine tumorsEuropean Journal of Endocrinology 2015; 172(1): R1 doi: 10.1530/EJE-14-0488
27
Ashley K. Clift, Henk Giele, Srikanth Reddy, Rubens Macedo, Adil Al-Nahhas, Harpreet S. Wasan, Gabriel E. Gondolesi, Rodrigo M. Vianna, Peter Friend, Anil Vaidya, Andrea Frilling. Neoadjuvant peptide receptor radionuclide therapy and modified multivisceral transplantation for an advanced small intestinal neuroendocrine neoplasm: an updated case reportInnovative Surgical Sciences 2017; 2(4): 247 doi: 10.1515/iss-2017-0025
28
Sandip Basu, Rahul V. Parghane, Vikas Ostwal, Shailesh V. Shrikhande. Neoadjuvant strategies for advanced pancreatic neuroendocrine tumorsNuclear Medicine Communications 2018; 39(1): 94 doi: 10.1097/MNM.0000000000000776
29
Deborah Pencharz, Gopinath Gnanasegaran, Shaunak Navalkissoor. Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapyThe British Journal of Radiology 2018; 91(1091): 20180108 doi: 10.1259/bjr.20180108
30
Sander M. Bison, Mark W. Konijnenberg, Marleen Melis, Stefan E. Pool, Monique R. Bernsen, Jaap J. M. Teunissen, Dik J. Kwekkeboom, Marion de Jong. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developmentsClinical and Translational Imaging 2014; 2(1): 55 doi: 10.1007/s40336-014-0054-2
31
Andrea Frilling, Ashley K. Clift. Therapeutic strategies for neuroendocrine liver metastasesCancer 2015; 121(8): 1172 doi: 10.1002/cncr.28760
32
Francesca Muffatti, Mauro Cives, Stefano Partelli, Franco Silvestris, Massimo Falconi. Neuroendocrine Tumors in Real Life2018; : 235 doi: 10.1007/978-3-319-59024-0_17
33
Andrea Frilling, Irvin M Modlin, Mark Kidd, Christopher Russell, Stefan Breitenstein, Riad Salem, Dik Kwekkeboom, Wan-yee Lau, Catherine Klersy, Valerie Vilgrain, Brian Davidson, Mark Siegler, Martyn Caplin, Enrico Solcia, Richard Schilsky. Recommendations for management of patients with neuroendocrine liver metastasesThe Lancet Oncology 2014; 15(1): e8 doi: 10.1016/S1470-2045(13)70362-0
34
Esther I. van Vliet, Jaap J.M. Teunissen, Boen L.R. Kam, Marion de Jong, Eric P. Krenning, Dik J. Kwekkeboom. Treatment of Gastroenteropancreatic Neuroendocrine Tumors with Peptide Receptor Radionuclide TherapyNeuroendocrinology 2013; 97(1): 74 doi: 10.1159/000335018
35
Tanaz Vaghaiwalla, Brian Ruhle, Kelvin Memeh, Peter Angelos, Edwin Kaplan, Chih-Yi Liao, Blase Polite, Xavier Keutgen. Response rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategiesSurgery 2020;  doi: 10.1016/j.surg.2020.04.001
36
James R. Howe, Nipun B. Merchant, Claudius Conrad, Xavier M. Keutgen, Julie Hallet, Jeffrey A. Drebin, Rebecca M. Minter, Terry C. Lairmore, Jennifer F. Tseng, Herbert J. Zeh, Steven K. Libutti, Gagandeep Singh, Jeffrey E. Lee, Thomas A. Hope, Michelle K. Kim, Yusuf Menda, Thorvardur R. Halfdanarson, Jennifer A. Chan, Rodney F. Pommier. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine TumorsPancreas 2020; 49(1): 1 doi: 10.1097/MPA.0000000000001454
37
Ashley Kieran Clift, Andrea Frilling. Management of patients with hepatic metastases from neuroendocrine tumorsAnnals of Saudi Medicine 2014; 34(4): 279 doi: 10.5144/0256-4947.2014.279
38
B. L. R. Kam, J. J. M. Teunissen, E. P. Krenning, W. W. de Herder, S. Khan, E. I. van Vliet, D. J. Kwekkeboom. Lutetium-labelled peptides for therapy of neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging 2012; 39(S1): 103 doi: 10.1007/s00259-011-2039-y
39
Pamela Moyade, Sobhan Vinjamuri. The heart mattersNuclear Medicine Communications 2019; 40(10): 1081 doi: 10.1097/MNM.0000000000001064
40
Amir Sabet, Hans-Jürgen Biersack, Samer Ezziddin. Advances in Peptide Receptor Radionuclide TherapySeminars in Nuclear Medicine 2016; 46(1): 40 doi: 10.1053/j.semnuclmed.2015.09.005
41
Eric H. Liu, Irvin Modlin. Therapeutic Nuclear MedicineMedical Radiology 2013; : 909 doi: 10.1007/174_2013_808
42
Anna Sowa-Staszczak, Dorota Pach, Robert Chrzan, Małgorzata Trofimiuk, Agnieszka Stefańska, Monika Tomaszuk, Maciej Kołodziej, Renata Mikołajczak, Dariusz Pawlak, Alicja Hubalewska-Dydejczyk. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)European Journal of Nuclear Medicine and Molecular Imaging 2011; 38(9): 1669 doi: 10.1007/s00259-011-1835-8